Oncothyreon Inc. (Nasdaq: ONTY) launched a global Phase 3 clinical trial of the cancer vaccine Stimuvax sending the stock price soaring 75 cents to close at $3.03.
Oncothyreon Launches Phase 3 Clinical Trial
June 22, 2009 at 17:46 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.